Ultima-Tesamorelin 5mg

MANUFACTURER Ultima Pharmaceuticals - United States
WAREHOUSE USA Warehouse 5
SUBSTANCE GHRH Peptide

For your safety, products are shipped without brand labels.

Tesamorelin is crafted using the growth hormone-releasing factor (GRF) and is specifically formulated to target excess abdominal fat linked to certain HIV treatments, a condition known as lipodystrophy.

Please note that Tesamorelin is not designed for weight loss and should not be used for obesity management.

Indicated for HIV-positive patients experiencing lipodystrophy, Tesamorelin (administered via injection) effectively aids in reducing excess abdominal fat.

Usage Limitations:

• The long-term safety of Tesamorelin and its potential cardiovascular advantages are yet to be thoroughly assessed. It is essential to evaluate the continuation of treatment for patients who do not show significant efficacy, which is determined by reductions in visceral adipose tissue as measured by waist circumference or CT scans.
• Tesamorelin is not approved for weight loss management and exhibits a weight-neutral effect.
• Currently, there is no evidence to suggest that Tesamorelin improves adherence to anti-retroviral therapies among HIV-positive individuals.

General Dosing Guidelines:

The recommended dosage of Tesamorelin is 2 mg, to be administered subcutaneously once daily.

For optimal results, the preferred injection site is the abdomen, and it?s advisable to rotate injection areas within this region. Please avoid injecting into scar tissue, bruises, or the navel.

Reconstitution Instructions:

Tesamorelin should be reconstituted using the provided diluent.

To prepare a 2 mg vial of Tesamorelin, add 2.1 mL of diluent and gently roll the vial in your hands for 30 seconds without shaking.

For comprehensive reconstitution guidelines, please refer to the INSTRUCTIONS FOR USE leaflet included with the Tesamorelin and diluent packages.

After reconstitution, administer Tesamorelin immediately and dispose of any unused solution. If not used right away, discard the reconstituted solution, and do not freeze or refrigerate it.

Administration:

Always visually inspect the reconstituted Tesamorelin solution for any particles or discoloration before use. The injection should only be performed if the solution is clear, colorless, and free of particulate matter.

Inject Tesamorelin subcutaneously into the abdominal skin, rotating injection sites to different areas. Avoid areas of scar tissue, bruises, or the navel.